Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation

Fu Siong Ng*, Ondřej Toman, Jan Petru, Petr Peichl, Roger A. Winkle, Vivek Y. Reddy, Petr Neuzil, R. Hardwin Mead, Norman A. Qureshi, Zachary I. Whinnett, David W. Bourn, M. Brent Shelton, Josef Kautzner, Arjun D. Sharma, Meleze Hocini, Michel Haïssaguerre, Nicholas S. Peters, Igor R. Efimov

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Objectives: This first-in-human feasibility study was undertaken to translate the novel low-voltage MultiPulse Therapy (MPT) (Cardialen, Inc., Minneapolis, Minnesota), which was previously been shown to be effective in preclinical studies in terminating atrial fibrillation (AF), into clinical use. Background: Current treatment options for AF, the most common arrhythmia in clinical practice, have limited success. Previous attempts at treating AF by using implantable devices have been limited by the painful nature of high-voltage shocks. Methods: Forty-two patients undergoing AF ablation were recruited at 6 investigational centers worldwide. Before ablation, electrode catheters were placed in the coronary sinus, right and/or left atrium, for recording and stimulation. After the induction of AF, MPT, which consists of up to a 3-stage sequence of far- and near-field stimulation pulses of varied amplitude, duration, and interpulse timing, was delivered via temporary intracardiac leads. MPT parameters and delivery methods were iteratively optimized. Results: In the 14 patients from the efficacy phase, MPT terminated 37 of 52 (71%) of AF episodes, with the lowest median energy of 0.36 J (interquartile range [IQR]: 0.14 to 1.21 J) and voltage of 42.5 V (IQR: 25 to 75 V). Overall, 38% of AF terminations occurred within 2 seconds of MPT delivery (p < 0.0001). Shorter time between AF induction and MPT predicted success of MPT in terminating AF (p < 0.001). Conclusions: MPT effectively terminated AF at voltages and energies known to be well tolerated or painless in some patients. Our results support further studies of the concept of implanted devices for early AF conversion to reduce AF burden, symptoms, and progression.

Original languageEnglish (US)
Pages (from-to)988-999
Number of pages12
JournalJACC: Clinical Electrophysiology
Issue number8
StatePublished - Aug 2021


  • MultiPulse Therapy
  • atrial fibrillation
  • cardioversion
  • defibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation'. Together they form a unique fingerprint.

Cite this